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Chronic kidney disease (CKD) is a worldwide public health
problem with significant comorbidity and mortality.
Improving quality of life and survival of CKD patients
necessitates a large number of preventive and therapeutic
interventions. To resolve these issues several organizations
have developed guidelines, which are difficult to compare
comprehensively. The Kidney Disease: Improving Global
Outcomes website at http://kdigo.org compares five major
guidelines. The section ‘compare guidelines’ covers 41 topics
distributed over five major subjects: (1) general clinics; (2)
hemodialysis (HD); (3) vascular access for HD; (4) peritoneal
dialysis; and (5) chemistries. The tables compare guideline
recommendations and the evidence levels on which they are
based, with direct links to each of the guidelines. These data
show that the different guideline groups tend to propose
similar targets, but that nuances in the guideline statements,
their rationale, and grading of evidence levels present some
discrepancies, although most guidelines are based on the
same literature. We conclude that there is an urgent need to
harmonize existing guidelines, and for a global initiative to
avoid the parallel development of conflicting guidelines on
the same topics. The tables displayed on the website offer a
basis for structuring this process, a procedure which has
recently been initiated by a body composed of the five
guideline development groups.
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The increase in available diagnostic and therapeutic alter-
natives in medicine that began after the Second World War
has escalated exponentially over the past three decades, as has
the literature supporting or refuting them. The quality of
these publications is variable and their conclusions often
equivocal. As a result of this information overload, it has
become increasingly difficult for the busy practitioner to
assess and critically evaluate the information necessary for
appropriate diagnostic and therapeutic decisions. This
weakness has been used to good advantage by the
pharmaceutical industry and likely accounts for some of
the variations in practice reported in outcome studies.1 To
support physicians in their desire to practice evidence-based
medicine, various organizations have developed clinical
practice guidelines, which draw on systematic review and
critical analysis of primary research studies, particularly
randomized controlled trials, to make specific recommenda-
tions assisting practitioners and patients in making decisions
about appropriate health care.
This wealth of available guidelines, however, also results in
variable and sometimes apparently contradictory recommend-
ations that stem principally from differences in the processes of
retrieving literature, grading the strength of the evidence, using
opinion and standards of care to construct guidelines where
research data is lacking, and considerations of regional
resources and policies. Some incongruity is inevitable,
particularly around non-critical areas, but when inconsisten-
cies on critical recommendations occur, particularly when they
are unexplained, confusion, criticism, and even resistance to
adoption of guidelines by practitioners is likely to occur. Thus,
what started as an attempt to deal with an overload of
information has now become an overload of sometimes
controversial guidelines.2 These abundant guidelines, however,
can be used constructively by comparing apparent differences,
identifying their reasons, and harmonizing their recommenda-
tions where possible.
One of the areas in which a large number of potentially
inconsistent guidelines have been generated is nephrology.
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This reflects a recent recognition in the nephrology commu-
nity that practice should be based on evidence, where
possible, and that a pathogenetic understanding of the
disease alone is insufficient to informed practice. Over the 13
years after the publication of the first nephrology clinical
practice guideline on the adequacy of hemodialysis (HD)3
there are now well over 100 nephrology guidelines, developed
by various regional organizations to guide the care of the
growing number of patients with end-stage renal disease on
renal replacement therapy4,5 and the even larger number of
cases at earlier stages of chronic kidney disease (CKD)
variously estimated at 50–100 per end-stage renal disease
case.6–9 One of the major comorbidities of CKD necessitating
continuous attention and therapeutic flexibility is the high
risk for cardiovascular morbidity and mortality, and one of
the expectations about guidelines is that they will be helpful
to reduce the prevalence of kidney disease and improve
outcomes for these patients.10–13
The Kidney Disease: Improving Global Outcomes (KDI-
GO) initiative was launched in January 2003, ‘to improve the
care and outcomes of kidney disease patients worldwide
through promoting coordination, collaboration and integra-
tion of initiatives to develop and implement clinical practice
guidelines’.14 Apart from several other activities, related to
grading the evidence of guideline recommendations, the
KDIGO Board of Directors also decided to develop a step-
wise approach to coordinating nephrology guidelines. As a
first step a website was constructed offering a comprehensive
overview of available nephrology guidelines. One of the
features offered by this website is the possibility to compare
directly five principal nephrology guidelines. The purpose of
the present report is to highlight the differences between
several available guidelines by comparing and critically
evaluating their recommendations displayed on the KDIGO
website, with the purpose to outline a basis for future
harmonization strategies.
RESULTS
Forty one topics were initially selected for inclusion in the
compare guidelines section of the website, and are classified
according to five major subjects: (1) general clinics; (2) HD;
(3) vascular access for HD; (4) peritoneal dialysis; and (5)
chemistries (Table 1). Topics were selected by the Database
Work Group of KDIGO. Not all guideline groups cover the
same topics. Subdivided per guideline, Caring for Australians
with Renal Impairment (CARI) discusses 30 of the selected
topics, Canadian Society of Nephrology (CSN) 16, European
Best Practice Guidelines (EBPG) 35, Kidney Disease Out-
comes Quality Initiative (K/DOQI) 30, and the UK guide-
lines 28. All five guidelines address target hemoglobin (Hgb)
in HD and peritoneal dialysis, time of referral to the
nephrologist, HD dose (Kt/Vurea), time to start dialysis,
prevention of infection of central venous catheters, target
parameters for iron reserve, and methods for estimation of
kidney function. By contrast, some other important topics,
such as mineral metabolism in stage 3 and 4 CKD are
considered by only two of the guidelines (K/DOQI and
EBPG), whereas others such as anticoagulation in HD for
patients with bleeding risk, general treatment of vascular
access infections, and target blood pressure in peritoneal
dialysis patients are discussed by only one of the guidelines
(EBPG for the first two topics, and UK guidelines for the
last).
The website, which also lists the evidence level per source,
demonstrates that for recommendations made on the same
problem in various guidelines different grades are given for
Table 1 | Compare guideline overview
General clinics
Target Hgb
Mineral metabolism targets: stage 3
Mineral metabolism targets: stage 4
Target blood pressure
Preferred nephroprotective agents
Protocol for hepatitis b vaccination
Time referral to the nephrologist
Cardiovascular screening in kidney disease
Hemodialysis
Target Hgb
Kt/V urea
Mineral metabolism targets: stage 5
Target blood pressure
Middle molecule removal
Bacteriological dialysate purity
Anticoagulation (HD) with bleeding risk
Anticoagulation (HD) without bleeding risk
Anticoagulation for HIT
Time to start dialysis
Chemical dialysate purity
Vascular access for HD
Preferred HD vascular access
Prevention of infection (general)
Prevention of infection (AV-fistula)
Prevention of infection (AV-graft)
Prevention of infection (central vein catheter)
Treatment of infection (general)
Treatment of infection (AV-fistula)
Treatment of infection (AV-graft)
Treatment of infection (central vein catheter)
Peritoneal dialysis
Target Hgb
Mineral metabolism targets: stage 5
Target blood pressure
Time to start dialysis
Adequacy of PD
Treatment of peritonitis
Treatment of exit site infection
Prevention of exit site infection and peritonitis
Chemistries
Target lipid concentrations
Target CRP
Target CO2
Target parameters iron reserve
Estimation kidney function
AV, arteriovenous; CO2, bicarbonate; CRP, C-reactive protein; HD, hemodialysis; HIT,
heparin-induced thrombocytopenia; Kt/V, ratio of clearance multiplied by time over
distribution volume; PD, peritoneal dialysis.
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the level of available evidence. To illustrate the problems
encountered, three specific topics are discussed in more detail
in the following section: (1) HD dose; (2) target Hgb levels;
and (3) bone and mineral metabolism targets. These topics
were chosen because all or most guideline groups covered
them and because they are major clinical issues in nephrology
practice.
HD dose (Kt/Vurea)
Table 2 summarizes information on the recommended dose
of HD (Kt/Vurea) that can be obtained from the website. At
first glance, all guidelines recommend similar targets, that is,
1.2 (CARI), 41.2 (UK) and X1.2 (EBPG, K/DOQI, CSN).
Closer scrutiny of the data however reveals that the targets for
EBPG and UK are expressed as equilibrated Kt/V (eKt/V),
whereas those of CARI, CSN, and K/DOQI are expressed as
single pool Kt/V (spKt/V). The eKt/V utilizes an equilibrated
urea level post-dialysis which provides a more accurate
picture of the delivered dose than does single pool kinetic
modeling.15–17 Consequently, eKt/V values are lower than
their equivalent single pool values by about 0.2. Hence, EBPG
and the UK guidelines target at a higher relative dose than the
other guidelines, which aim at X1.2 spKt/V.
Moreover, the EBPG propose a prescribed dose of 1.4
(spKt/V) as a target with the intent of achieving a delivered
dose of spKt/V of 1.2 in the majority of patients. On the other
hand, both CARI and K/DOQI fix their target delivered dose
at 1.2 (spKt/V) but advise a prescribed dose of 1.3 in order to
achieve 1.2 in the majority of patients. Of note, most of these
guidelines were published in 2002 or earlier, and are
essentially based on observational studies.18–20 The only
recent randomized clinical trial evaluating the potential
impact of HD dose on outcome is the hemodialysis (HEMO)
Study, which was published at the end of 2002, that is, after
the publication of the guidelines.21 The HEMO Study found
no difference in outcome between a group targeted at Kt/V
values just above the proposed recommendations (1.32 spKt/V)
versus another group with a higher dose of 1.71 spKt/V. The
conclusions of the HEMO Study support the recommenda-
tions of the current guidelines since there seems to be no
extra benefit overall in raising Kt/V above the minimum
target of 1.32 single pool examined in the HEMO Study.
The comparison of evidence levels among guidelines is
hampered by the use of different grading systems (A–C; A, B
and opinion; I–IV; I–IV and opinion; or simply ‘Evidence’) by
different guideline groups or by the same organization at
different moments. For the sake of uniformity, we translated
the evidence levels in the website tables and also in Tables 2–4
of this paper, into the KDIGO grading system for the
discussion that follows.22 The KDIGO system is the most
nuanced and recent one, which in the meanwhile has been
adopted in the most recent guidelines of CARI and K/DOQI.
The translation of the different types of evidence scoring into
the KDIGO system is summarized in Table 5.
When applying this system for uniformization, the
evidence levels of the guidelines discussed in this paragraph
appear fairly similar, with the equivalents of KDIGO I-IV
being proposed by K/DOQI, III-IV by CARI, EBPG, and UK,
and III by CSN.
This comparison demonstrates that although many guide-
lines propose similar targets, there are minor differences. In
this case the apparent differences are principally due to
different expressions of the unit dose of HD. Given the
absence of randomized controlled trial (RCT) data demons-
trating what an appropriate dose of HD is, some variability in
the guidelines is reasonable.
Table 2 | Comparative data regarding Kt/Vurea for hemodialysis
Origin Year Target Method Comments Evidence
CARI 2000 1.2 spKt/V Aim at 1.3 to deliver 1.2 III–IV
CSN 1999 X1.2 spKt/V III
EBPG 2002 X1.2 eKt/V B
=B1.4 spKt/V 1.4 proposed to deliver 1.2 (sp)
K/DOQI 2002 X1.2 spKt/V Aim at 1.3 to deliver 1.2 Evidence
UK 2002 41.2 eKt/V B
Abbreviations of guideline names (origin): see Table 5; spKt/V, single pool Kt/V; eKt/V, equilibrated Kt/V.
For comparison of different evidence scoring systems, please refer to Table 5.
Table 3 | Comparative data regarding target Hgb levels
Origin Year Target Comments Evidence
CARI 2005 X11 g/dl p12 g/dl in CVD III–IV; comment: I
CSN 1999 11–12 g/dl Opinion
EBPG 2004 411 g/dl Not412 g/dl in severe CVD B
Not414 g/dl globally
K/DOQI 2001 11–12 g/dl Targets for EPO, not for transfusion Evidence
UK 2002 410 g/dl A
Abbreviations of guideline names (origin): see Table 5. CVD, cardio-vascular disease; EPO, erythropoietin.
For comparison of different evidence scoring systems, please refer to Table 5.
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Target Hgb levels
All guidelines propose a minimum target of 11 g/dl with the
exception of the UK guidelines, which recommend a
minimum of 10 g/dl (Table 3). The rationale to adhere to
the 10 g/dl is based on two RCTs.23,24 An additional argument
mentioned in the UK guidelines for proposing a relatively
lower target is related to cost. Of note, the normal Hgb study
which is one of the publications providing the basis of the
UK guideline was undertaken in subjects more than 65 years
old, close to 70% of whom had grafts as vascular access; in
addition, this study was confined to patients with severe
cardiovascular disease, not to a prevalent population of
dialysis patients, and was terminated earlier than planned
because of safety concerns.23 The other guidelines, although
proposing a higher minimal target, are based on the same
literature.
The CSN and K/DOQI guidelines propose maximum
target Hgb of 12 g/dl. Likewise, the EBPG and CARI suggest
avoiding values in excess of 12 g/dl, but only in patients with
severe cardiovascular disease, based on the results of the
normal Hgb study, although the cutoff of that study was
higher (Hgb 14 g/dl).23 The EBPG discourages values 414 g/
dl overall, out of concern for hemoconcentration, especially
at the end of the HD session, when the plasma volume is
most reduced by ultrafiltration.25
Of note, the same target recommendations are made in
most guidelines for non-dialyzed CKD patients and those on
peritoneal dialysis, although the cited studies were not
designed for these populations, and unlike HD those patients
are not subject to ultrafiltration produced hemoconcentration.
For this topic, evidence levels are quite divergent:
equivalent to KDIGO level I–II in the UK guidelines, level
I–IV for K/DOQI, and level III–IV for EBPG and CARI. CSN
refers to opinion-based evidence, and this in spite of it being
based on the same literature, comprising relevant RCTs. It is
difficult to speculate on the divergence in grading these
evidence levels, but some guidelines may take into account
only the design of the study to attribute level I–II and do this
automatically with at least one RCT, whereas other guidelines
require several RCTs or take into account the quality of the
studies to downgrade or upgrade evidence levels.
Mineral metabolism targets
CSN formulated no guidelines regarding this issue (Table 4).
European recommendations were issued by an expert panel
not operating under EBPG, and later on EBPG generated
limited guidelines only concerning phosphorus and para-
thyroid hormone in the first wave of the HD guidelines
(section VII on vascular disease and risk factors). Only the
European expert panel and the K/DOQI stratify their
recommendations according to the different stages of CKD.
The European panel recommendations are the same for all
stages, whereas in K/DOQI the target Ca and P are the same
in stage 3 and 4, but are allowed to be higher in stage 5. Also,
recommended parathyroid hormone targets are gradually
increased in K/DOQI for the progressive stages of CKD but
these are opinion-based targets and the rationale for higher
targets in the more advanced stages is not always evident.
There is considerable disparity in proposed target values.
Values for phosphorus are the most consistent, probably
Table 4 | Comparative data regarding mineral metabolism targets
Origin Year Ca P CaP PTH Evidence
CKD stagea 3 (GFR 30–59 ml/min/1.73m2)
Europeb 2001 8.8–11.0 mg/dl 2.5–4.6 mg/dl — 85–170 pg/ml Opinion
K/DOQI 2003 8.4–9.5 mg/dl 2.7–4.6 mg/dl — 35–70 pg/ml P: Ev, Opin
Ca: Ev
PTH; Opin
CKD stagea 4 (GFR 15–29 ml/min/1.73m2)
Europeb 2001 8.8–11.0 mg/dl 2.5–4.6 mg/dl — 85–170 pg/ml Opinion
K/DOQI 2003 8.4–9.5 mg/dl 2.7–4.6 mg/dl o55 mg2/dl2 70–110 pg/ml P: Ev, Opin
Ca: Ev
PTH; Opin
CKD stagea 5 (GFR o15 ml/min/1.73m2 or renal replacement therapy)
CARI 2000 8.8–10.4 mg/dl o6.8, o71.9 mg2/dl2 2–3 limit B
pref o5.6 mg/dl —
Europeb 2001 8.8–11.0 mg/dl 2.5–4.6 mg/dl — 85–170 pg/ml Opinion
EBPGc 2002 — 2.5–5.5 mg/dl o55 mg2/dl2 — B
K/DOQI 2003 o10.2 3.5–5.5 mg/dl o55 mg2/dl2 150–300 pg/ml P, PTH: Opin
pref 8.4–9.5 mg/dl Ca: Opin
UK 2002 8.8–10.4 mg/dld — o4 limit B
Abbreviations of guideline names (origin): see Table 5. Ca, calcium; Ca P, calcium-phosphorus product; CKD, chronic kidney disease; Ev, Evidence; GFR, glomerular filtration
rate; Opin, Opinion; P, phosphorus; pref, preferably; PTH, parathyroid hormone.
aStaging of CKD as adhered to by K/DOQI3 and KDIGO.4
bEuropean recommendations based on clinical algorithms developed by a European expert panel not operating under EBPG.
cHemodialysis guidelines, section VII – Vascular disease and risk factors.
dAdjusted for serum albumin.
For comparison of different evidence scoring systems, please refer to Table 5.
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because a number of observational studies show a distinct
increase in morbidity and mortality at increasing phosphorus
levels.26–28 Only three guidelines (EBPG, K/DOQI, and
CARI) give a target value for Ca P product. Although
those values diverge by more than 30%, they are based on the
same study.26 The EBPG and K/DOQI take into account that
mortality starts to rise once the product exceeds 4.2 mmol2/l2
(55 mg2/dl2) whereas CARI focuses on the fact that the
increase in mortality becomes significant only with a Ca P
product in excess of 5.8 mmol2/l2 (71.9 mg2/dl2).
Only the UK and CARI guidelines consider that the
various test methods used to measure parathyroid hormone
may have a different sensitivity causing different results. This
bias is avoided in those guidelines by expressing the target
parathyroid hormone not as absolute values but as a multiple
of the highest normal value.
Evidence levels are again divergent between the different
guidelines with KDIGO equivalent I–IV, III–IV, and opinion
(Table 4). Here again, the reasons for these discrepancies are
not obvious. Any evidence level below III is debatable given
the absence of RCTs, and the disparity is partly due to the fact
that K/DOQI gives ‘Evidence’ as qualification, without
specification of the exact level.
DISCUSSION
The current evaluation comparing recommendations offered
by five major national and international nephrology guide-
lines regarding 41 topics is based on the data displayed in the
compare guidelines section of the KDIGO website. It is clear
that: (1) not all topics are covered by all guidelines and there
is a marked disparity in the items considered in the different
guidelines; (2) only a few topics (9/41) are covered by all
Table 5 | System of evidence grading, by guideline groupa
Source Evidence level
Comparison with KDIGO
classification
KDIGO I: Meta-analysis of several controlled studies
II: Controlled randomized study
III: Case control or observational study
IV: Case reports
Opinion
CARI-Australia I: Evidence obtained from a systematic review of all relevant RCT’s Equal to KDIGO system
II: Evidence obtained from at least one properly designed RCT
III: Evidence obtained from comparative studies (cohort, case control)
IV: Evidence obtained from case series
CSN-Canada I: RCT which demonstrates a statistically significant difference in at least one
important outcome or a RCT of adequate size to exclude a 25% difference in
relative risk with 80% power given the observed results.
I–II equals7I–II KDIGO
II: CT which does not meet the level I criteria III–VI equals7III–IV KDIGO
III: A non-randomized trial with contemporaneous controls selected by some
systematic method.
IV: A before–after study of case series (at least 10 patients) with historical
controls.
V: Case series (at least 10) without controls
VI: Case report (o10 pts)
EBPG-Europe According to the categories of the US Department of Health and Social
Services (1992)
A equals I–II KDIGO
A: Evidence from at least one prospective randomized controlled trial or from
meta-analyses of several controlled trials
B equals III–IV KDIGO
B: Evidence from qualitatively satisfactory but uncontrolled open studies C equals opinion KDIGO
C: Opinions of consensus groups such as the NKF-DOQI Work Group
K/DOQI-US Evidence Evidence equals I–II–III
Opinion or IV KDIGO
UK-Guidelines The term ‘standard’ is used when the available evidence is strong or for key
‘good practice’ statements
A equals I–II KDIGO
B equals III–IV KDIGO
Recommendation is used where the available evidence is weaker and for ‘good
practice’ statements.
C equals Opinion KDIGO
A: Evidence from randomized controlled trials or meta-analysis of several
controlled trials
B: Well conducted trials but no randomized trials
C: Expert opinions
CARI, Caring for Australians with Renal Impairment. CSN, Canadian Society of Nephrology; CT, controlled trial; EBPG, European Best Practice Guidelines; K/DOQI, Kidney
Disease Outcomes Quality Initiative; RCT, randomized controlled trial; UK, Renal Association Guidelines.
aEvidence scoring as used in the most recent guidelines; older guidelines may use different systems.
1058 Kidney International (2007) 71, 1054–1061
o r i g i n a l a r t i c l e H Vanbelleghem et al.: The Kidney Disease: Improving Global Outcomes
guidelines; (3) there is an appreciable difference among
guidelines in the system of grading the level of evidence; and
(4) there is considerable disparity among guidelines in the
recommendations and the level of evidence given for the
same topics. As illustrated by the specific examples of
guidelines dealing with dialysis adequacy, target Hgb and
mineral metabolism targets, the different guidelines do not
come to uniform recommendations in spite of apparently
being based on the same literature.
Why some guideline groups choose certain topics and
others not, is not always clear. This likely reflects the
evolutionary process through which nephrology developed as
a discipline, the clear disparity in target dialysis dose that
existed through the 1990s when nephrology guidelines were
first published, and the fact that a definition and classifica-
tion of CKD was not adopted until 2002.
There appears to be a lack of uniformity in the process of
guideline development, even in such a well-circumscribed
area as nephrology. This inconsistency is confusing to
practitioners concerned with best practice. It could be
resolved if we move toward more harmonized global
guidelines, based on a uniform process for their develop-
ment. The concept and design of the KDIGO website is to
provide a framework that highlights those differences and can
be used as a first step to identify reasons for variability and to
introduce improvements in the guideline development
process. An initial effort to this end has been initiated at a
recent meeting of the five guideline groups. Such a model
would be applicable to guidelines in general, independent of
the specialties for which they were developed.
To the best of our knowledge, there are virtually no
sources allowing a similar comparison of other medical
guidelines. A Google search of the Internet with the keywords
‘medical’, ‘guideline’, and ‘comparison’, displayed only one
relevant hit, which was the website of the ‘National Guideline
Clearinghouse’.29 The latter allows access to different guide-
lines of various specialties, but does not allow for a direct
comparison of topics, of recommended targets, or the
evidence level of recommendations.
Based on the results illustrated in the present report it
would be expected that similar disparities would frustrate
guideline users in fields outside nephrology as well. The plea
for comparison and harmonization of guideline recommend-
ations should therefore be extended to all guideline areas.
This is the mission that KDIGO has undertaken for
nephrology guidelines.
The proposed different targets per guideline might have
important clinical and financial implications. For example,
the target Hgb levels may have an impact on cardiovascular
status and survival.30 Lower and higher target Hgb may result
in higher morbidity and mortality rates in a given
population.23,31 On the other hand, lower target Hgb levels
automatically imply a lower need for erythropoietin,32 which,
depending on the reimbursement system, may result in a
lower cost for society and/or the patient, and alter the profit
margin for a dialysis facility.
Harmonization of guidelines does not necessarily imply
that each country should follow these guidelines implicitly.
There should be room for consideration and adaptation to
available regional needs and resources, including appropriate
country-based thresholds for incremental cost effectiveness.
For example target Hgb levels may be impossible to reach in
certain countries due to socio-economic restraints. It might
therefore be useful to aim at a stepwise approach, whereby a
first global ideal target is proposed, followed by the
subsequent consideration of local reasons to fine-tune this
target. This is the process proposed by the World Health
Organization in its document (EIP/GPE/EQC/2003.1) titled
‘Guidelines for World Health Organization Guidelines’.33
Essentially, the process begins with guideline statements that
are of maximal benefit to individuals or groups of patients if
resources were unlimited. The next stage assesses tradeoffs
between cost of applying an intervention on a population
basis and its health impact (very limited versus unlimited
resources). The final stage is for local guideline groups to
adopt and prioritize recommendations for regional imple-
mentation based on the evidentiary basis of the global
guideline statements, if necessary with assistance from the
global guideline development group. This is the approach
adopted by KDIGO in developing its new guidelines, now at
various levels of progress, on Hepatitis C, Mineral and Bone
Disease, and Care of the Kidney Transplant Recipient.
Uniformity of grading the level of evidence remains one of
the principal approaches to provide a comparative basis to
the strength of recommendations in various guidelines.
Unfortunately evidence levels are graded using different
methods by various organizations. As shown in the discus-
sion of the specific topics, reported evidence levels diverge
among guidelines in nephrology. Comparison between
guidelines is therefore difficult and somewhat arbitrary.
Some of the discrepancies may reflect an evolution of
evidence as new publications appear over time. More
frequently, they point to differences in methods of grading
the evidence.
Attempts to resolve these discrepancies have been under-
taken by different international groups of experts such as the
Relevance, Education, Applicability, Discrimination and
overall Evaluation method (READER)34 and the Grading of
Recommendations Assessments, Development and Evalua-
tion system.35 KDIGO will use in the future the Grading of
Recommendations Assessments, Development and Evalua-
tion system, which allows upgrading or downgrading of
evidence levels.22 KDIGO will additionally apply the
Appraisal of Guidelines Research and Evaluation instrument,
which assesses 23 key items in six different domains and has
already been validated extensively.36 The advantage of the
Appraisal of Guidelines Research and Evaluation instrument
is the applicability for any disease in any country.
One of the problems encountered in developing guidelines
in nephrology is a relative scarcity of valid randomized
controlled studies of acceptable quality.37 International,
multicenter randomized studies on an independent basis
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should be undertaken to overcome this gap. Financial
resources that are now used to develop a multiplicity of
parallel guidelines might become available for redistribution
to those studies as well as to the development of guidelines
on topics which have not been dealt with until now.
Of note, the data in this article are based on a fixed time
status of the KDIGO website and only on the five guidelines
on which this website is based currently. Evidence-based
guidelines, given their very nature, should be updated
regularly, in light of newly available data; updates of the
K/DOQI guidelines on anemia have recently been pub-
lished38 and several CARI and CSN updates have ap-
peared.39,40 Also updates of the UK guidelines are under
way. Although such modifications may reduce discrepancies
with other guidelines, they may not necessarily do so; even if
this were the case, the main message of the present article,
which points to the potential at large for internal discordance
among guidelines at any moment remains valid, but deserves
ongoing updates. KDIGO has established a Liaison Task
Force of the five guideline groups to expedite entry and
comparison of new and updated guidelines.
The following steps will be implemented in the coming
months to improve the design of the website: (1) the addition
to the tables of information on new or recently updated
guidelines; (2) the extension of the number of topics for the
comparison tables; (3) the installation of tools allowing
website visitors to make interactive comments; (4) the
installation of buttons allowing to move back and forth
between different tables; (5) the posting for specific entries
allowing public review of preliminary drafts of KDIGO
guidelines ; (6) the installation of links to short ‘rationale’
sections where guideline groups briefly explain how they
defined their targets; (7) inclusion of other than the five
currently displayed nephrology guidelines, if they conform
with the same preset conditions, as those used now to include
guidelines on the website; and (8) the addition to the website
of non-nephrology guidelines which are pertinent to
nephrologists.
CONCLUSION
The KDIGO initiative is the first international endeavor to
compare several existing nephrology guidelines and to
undertake the development of new global guidelines that
will be applicable worldwide. The KDIGO website with its
compare guidelines section offers the opportunity to consider
several different guidelines together, and to compare the
recommendations given in 41 selected topics, which are
considered to be germane for the treatment of CKD patients.
The data presented from the website show that: (1) topics
addressed by major guidelines are highly divergent; and (2)
proposed recommendations and evidence levels differ in spite
of being based on the same literature. These data endorse the
need for global and harmonized guidelines worldwide, rather
than launching separate and parallel activities that confuse
the potential users and at the practical level lead to inertia
rather than therapeutic improvement by the individual
practitioner.
MATERIALS AND METHODS
The website
The website is described, as it was available on 1 May 2006, owing to
the lag time in preparing this publication; it was necessary to focus
on data as they were available at a fixed moment, to avoid confusion
and inconsistencies. The layout and content of the website will be
modified in the future as a result of new guidelines and upcoming
updates. Also, discussion is currently underway for extension of the
existing guideline topics posted on the website. It is likely, therefore,
that by the time this report is published the website will be or has
been modified, as new guidelines appear or old ones are updated.
The website can be accessed at: http://kdigo.org. It contains
general information on the KDIGO initiative, a mission statement
and an option to link to the websites of the Dialysis Outcomes and
Practice Patterns Study, the United States Renal Data System and
information on the activities of the different KDIGO Work Groups.
Through guideline summaries it accesses all the different guideline
topics listed and through the compare guidelines section it provides
the details of each of the guidelines. The comparison of these
guidelines on common topics is the main focus of this paper.
The compare guidelines section of the website
In its present format, the compare guidelines section allows
comparison of five major guidelines, which have been selected by
the KDIGO guideline Database Work Group and approved by its
Board of Directors, based on the following criteria: (1) developed by
a panel of internationally or nationally recognized clinical experts;
(2) based on objective and well defined literature search and
structured analysis methods; and (3) subjected to a well defined
peer-review process.
The selected guidelines are: (1) the CARI guidelines CARI –
Australia-New Zealand; (2) the guidelines of the CSN – Canada; (3)
the EBPG – Europe; (4) the guidelines (K/DOQI – USA); and (5) the
Renal Association guidelines (UK). The topics selected for
comparison are shown in Table 1.
The data displayed in the compare guidelines section show:
(a) the selected individual topic; (b) the guidelines that address
that topic; (c) and the system of evidence level grading (Table 5).41
The guideline comparison tables contain the name of the guideline,
the year of publication, the recommendation, the source, additional
remarks, for example, the rationale of a given recommendation, and
the respective assigned level of evidence. The full text of that specific
guideline, its rationale and reference list, can be accessed by clicking
the source button.
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